Open AccessCD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function
Author(s) -
Moua Yang,
Roy L. Silverstein
Publication year - 2019
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000522
Subject(s) - platelet activation , cd36 , platelet , microbiology and biotechnology , signal transduction , dyslipidemia , hemostasis , immunology , biology , medicine , endocrinology , receptor , diabetes mellitus
Metabolic diseases, including dyslipidemia, diabetes mellitus, and chronic inflammation are risk factors for clinically significant thrombotic events. Thrombosis in these settings is multifaceted with coordinated mechanisms between platelet activation and the hemostatic pathways. This review focuses on recent advances in platelet procoagulant and apoptotic signaling with emphasis on the pathophysiologic mechanisms induced by platelet CD36 in dyslipidemia, and the key unaddressed questions relating to the field.